OPUS International
Industry Update - November 2025

Since the 2025 guidance took effect, the European Food Safety Authority (EFSA) has fundamentally changed how novel foods reach the EU market.

What was once a regulatory checkpoint is now a design constraint—especially for:
• Precision-fermented proteins
• Synthetic biology–derived ingredients
• Nano-enabled bioactives

🧪 The new normal
Robust tiered toxicology, advanced allergenicity bioinformatics, and full nano-characterisation are no longer edge cases—they’re baseline expectations. ADME data, longer repeated-dose studies, and deeper production transparency have become standard across successful dossiers.

🧬 Synthetic biology under the microscope
Whole-genome sequencing, metabolomics, and host-protein allergenicity assessments are now routine, pushing developers to address unintended effects early in R&D rather than at submission.

⏱️ What industry has learned
• Regulatory timelines average 18–24 months for advanced ingredients
• Safety packages often exceed €500k
• Projects aligned with EFSA guidance from day one move faster—and fail less often

🌍 Why this still matters globally
EFSA’s framework continues to influence FDA thinking and global alignment on novel proteins and nano-nutrients.
Takeaway:
In 2026, regulatory readiness isn’t compliance—it’s strategy.